Annual Meeting 2026

Save the Date - 22 - 25 June 2026

Annual Meeting 2026

VALIDATE’s 8th Annual Meeting will take place from 22–25 June 2026 in the vibrant city of Cartagena on the Caribbean coast of Colombia.

ECR Workshop - 22 June 2026

The 2026 Annual Meeting will open with a dedicated training day for Early Career Researchers, led by VALIDATE's own Samantha Vermaak and Dr María Adelaida Gómez. This year’s ECR Workshop will focus on grant writing, offering practical guidance on how to turn research ideas into competitive proposals. Through interactive sessions, participants will learn how to identify funding opportunities and structure applications effectively — gaining valuable insights from experienced researchers and grant reviewers.

A Three-Day Annual Meeting - 23 - 25 June 2026

Following the workshop, VALIDATE’s Annual Meeting returns — now extended to three full days to provide even more opportunities for networking, discussion, and collaboration. The meeting is free for VALIDATE members and will showcase cutting-edge vaccine research on our core pathogens: Mycobacteria, Leishmania, and Burkholderia pseudomallei (melioidosis). The expanded format includes talks from international experts, poster sessions, interactive discussions, and social events — an unmissable opportunity to connect with peers and leaders across the global vaccine community.

The Venue- The Hyatt Regecy, Cartagena 

Set on Cartagena’s Caribbean coastline, the Hyatt Regency Cartagena offers modern conference facilities, on-site accommodation, and excellent connectivity to the historic walled city. The venue provides an ideal setting for scientific exchange, networking, and collaboration, while also giving delegates the opportunity to experience one of Latin America’s oldest, most vibrant and culturally rich cities.

Hyatt Regence Cartagena

 

Your Safety and Travel to Colombia

The VALIDATE Management Team is monitoring international developments as we plan for the 2026 Annual Meeting. Based on current government travel advice, reputable news reporting, and guidance from our Colombian colleagues, we continue to plan for the meeting to take place in Colombia.

We recognise that the situation is complex and may evolve. The safety of our members and delegates remains our highest priority, and we will continue to monitor developments and adapt our plans if necessary, keeping members informed with clear and timely guidance. At this stage, we look forward to delivering a successful meeting in Colombia. If you have any questions, please contact the VALIDATE Team at VALIDATE@ndm.ox.ac.uk.

Provisional Agenda

Expand All

09:00 – 09:30

Registration & tea/coffee

09:30 – 09:35     Welcome

Prof Samantha Sampson — VALIDATE Network Director

09:35 – 09:55    VALIDATE Update

Mrs Samantha Vermaak — Co-Investigator & Executive Manager

09:55 – 10:40    Keynote Talk

10:40 – 11:00    Establishing the immunogenicity of the first naturally presented Leishmania epitope vaccine candidates in Ethiopian cutaneous leishmaniasis

Dr Thao-Thy Pham

11:00 – 11:20    Probing extreme phenotypes to determine correlates of risk for recurrent TB

Dr Happy Tshivhula

11:20 – 11:40    Microbicidal and regulatory functions of bovine neutrophils during Mycobacterium bovis infection

Dr Susana Flores Villalva

11:40 – 11:55    Fellow Q&A Panel

11:55 – 12:55     Lunch

12:55 – 13:25     Investigator Research Talk - TBC

13:25 – 13:45    Determining the metabolic impact of BCG vaccination

Dr Mrinal Das

13:45 – 14:05

Assessing the immunogenicity and protective efficacy of a telomerase-deficient Leishmania major

Dr Mark Shiburah

14:05 – 14:25    Accelerating BCG efficacy: targeting dendritic cell migration

Dr Luciana Balboa

14:25 – 14:40    Q&A Panel

14:40 – 15:10    Afternoon Break

15:10 – 15:40    Investigator Research Talk - TBC

15:40 – 16:55    Networking Session

Chaired by Samantha Vermaak

16:55 – 17:00    Wrap-Up

Sam Sampson

17:00 – 19:00    Poster Session & Drinks Reception

19:00 – 21:30    Annual Meeting Dinner

09:00 – 09:45    Keynote Talk TBC

09:45 – 10:05    Profiling the mycobacterial immune response in human lung tissue to inform novel TB vaccine design

Dr Alba Llibre

10:05 – 10:25    Burden of Burkholderia pseudomallei in Nepal to inform vaccine needs (BURNEP study)

Dr Suraj Bhattarai

10:25 – 10:45    Immune signatures of chronic tuberculosis and cutaneous leishmaniasis

Dr Menberework Negatue

10:45 – 11:00    Q&A Panel

11:00 – 11:30    Break

11:30 – 11:50    Boosting BCG vaccine efficacy through metabolic modulation of T memory stem cells

Dr Mariano Maio

11:50 – 12:10    Measuring the immunogenicity and efficacy of a novel DNA-launched therapeutic for tuberculosis

Dr Robert Krause

12:10 – 12:30    Preclinical evaluation of a recombinant chimeric vaccine for protection against tegumentary leishmaniasis

Dr Camila Freitas

12:30 – 12:45    Fellow Panel Discussion

12:45 – 13:45    Lunch

13:45 – 14:05    Evaluation of a recombinant chimeric protein vaccine with adjuvant for protection against visceral leishmaniasis

Dr Daniela Pagliara Lage

14:05 – 14:25    Defining the mechanism of BCG-priming and its impact on subunit vaccine boosting

Dr Elena Stylianou

14:25 – 14:45    Translating protective immune signatures in the lung to peripheral biomarkers for TB

Dr Paula Niewold

14:45 – 15:00 Activity TBC

15:00 – 15:30    Break

15:30 – 15:45    Innovative Diagnosis for PKDL / Leprosy — Project Update

Prof Mitali Chaterjee 

15:45 – 16:05    CCR4LEP: Exploring CCR4 as immune correlate of protection for leprosy

Dr Anouk van Hooij

16:05 – 16:25    Melio MuSe: Multiplex serology advancing multicomponent melioidosis vaccines

Dr Ivo Steinmetz

16:25 – 16:35    Q&A Panel

16:35 – 17:05    Investigator Research Talk TBC

17:05 – 17:10    Wrap up

10:00 – 10:45    Keynote Talk

10:45 – 11:30    Investigator Research Talk TBC

11:30 – 12:00    Break

12:00 – 12:20    Development of versatile and cost-effective next-generation vaccines through multivalent approaches

Dr Julen Tomás Cortázar

12:20 – 12:40    Comparative testing of Ag85 isoforms and consensus sequence optimisation for next-generation TB vaccines

Dr Andy Tran

12:40 – 12:50    Q&A Panel

12:50 – 13:50    Lunch

13:50 – 14:35    Director / Senior Investigator Talk

Dr Maria Adeliada Gomez

14:35 – 14:55    Evaluating the immunogenicity and efficacy of Curdlan-PLGA nanoparticles encapsulating Mycobacterium tuberculosis antigens

Dr Zimvo Obasa

14:55 – 15:15    Pilot study to investigate tissue-based immunological profiles associated with TB using single-cell spatial resolution in human lymph nodes

Dr Monika Looney

15:15 – 15:25    Fellow Panel Discussion

15:25 – 16:10    Activity TBC

16:10 – 16:20    Awards & Closing Remarks

Sam Sampson

Expand All

VALIDATE offers annual travel grants of up to £3,000 to LMIC members to attend the VALIDATE Annual Meeting (and ECR Workshop, if applicable). To apply, please consult the Annual Meeting Travel Grants guidance document for eligibility and funding details, complete every section of the application form, and submit it with all required documents using the portal below before the deadline of 30 January 2026.

We particularly encourage members from Latin American LMICs to apply for a VALIDATE Travel Grant, to cover their local travel and subsistence costs to join the 2026 Annual Meeting in-person.

Applications will be competitively reviewed by the VALIDATE Network Management Board.

We also invite you to submit a poster abstract for the Annual Meeting, which can strengthen your travel grant application. Further information on poster submissions can be found on the VALIDATE Annual Meeting webpage.

The VALIDATE Annual Meeting 2026 will include keynote talks, research presentations from VALIDATE-funded projects, and networking opportunities, as well as a Poster Session allowing members to showcase important areas of their research and discuss them in person with fellow VALIDATE members from around the world.

To get a sense of what a successful poster abstract looks like, have a look at those presented at the Annual Meeting 2025.

To submit a Poster abstract, please complete the application form and submit it via the portal below by 30 January 2026, after which the VALIDATE Network Management Board will competitively review submissions at their March meeting. Applicants will receive their review outcomes within a week of the board’s decision.

VALIDATE Investigator members are encouraged to apply to present a research talk at the 2026 VALIDATE Annual Meeting.

To submit a Research Talk abstract, please complete the application form by 30 January 2026, ensuring that all stated word limits are followed. Abstracts will be reviewed competitively by the VALIDATE Network Management Board during their March meeting, and applicants will be informed of the results within a week of the Board’s decision.